Derya ÖZYÖRÜK, Figen DOĞU, Deniz KARATAŞ, Nurdan TAÇYILDIZ, Aydan İKİNCİOĞULLARI, Emel CABI-UNAL, Gülsan YAVUZ, Handan DİNÇASLAN

Serum IL-13 levels at diagnosis and remission in children with malignant lymphoma

ÖzyörükD, Yavuz G, Dinçaslan H, Cabı-Unal E, TaçyıldızN, Karataş D, Doğu F, İkincioğulları A. Serum IL-13 levels at diagnosis and remission in children with malignant lymphoma. Turk J Pediatr 2016; 58: 246-253.Interleukin (IL)-13 has been reported to have a role in the pathogenesis of lymphoma through recent molecular studies predominantly in adult patients. As malignant lymphomas in children differ from adult counterparts in terms of histology and response to treatment, we aimed to determine the serum IL-13 levels of patients with lymphoma; its relation with clinical-laboratory parameters and to look for any correlation of serum IL-13 levels with different prognostic factors in children. Twenty-eight patients with malignant lymphoma and 20 age-matched healthy controls were included in the study. The median serum IL-13 level at diagnosis (range 0.59-68 pg/ml, median 3.40 pg/ml) was higher than that in remission (range 0.14-12.2 pg/ml, median 1.60 pg/ml) in the HL group (p

PDF

___

1. Hudson MM. Hodgkin lymphoma. In: Principles and Practice of Pediatric Oncology. Philadelphia: Lipincott Williams and Wilkins; 2006: 695-721.
2. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 2001: 38: 368-375.
3. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999: 189:1939- 1946.
4. Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001: 97: 250-255.
5. Defrance T, Carayon P, Billian G, et al. Interleukin 13 is a B cell stimulating factor. J Exp Med 1994: 179:135-143.
6. McKenzie AN, Culpepper JA, de Waal Malefyt R, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci U S A 1993: 90: 3735-3739.
7. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21: 425-456.
8. Fiumara P, Cabanillas F, Younes A. Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. Blood 2001: 98: 2877-2878.
9. Alexander S, Ferrando AA. Pediatric lymphoma. Nathan and Oski's Hematology and Oncology of Infancy and Childhood. Eight ed. Vol 2:1626-1672.
10. Lanzkowsky P. Hodgkin Disease. In: Manual of Pediatric Hematology and Oncology. (4th ed). San Diego: Elsevier Academic Press, 2005: 453-490.
11. Skinnider BF, Kapp U, Mak TW. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002; 43:1203-1210.
12. Skinnider BF, Kapp U, Mak TW. Interleukin 13: a growth factor in hodgkin lymphoma. Int Arch Allergy Immunol 2001; 126: 267-276.
13. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002: 99: 4283-4297.
14. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99: 618-626.
15. Gaiolla RD, Domingues MA, Niero-Melo L, de Oliveira DE. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med 2011; 135: 483-489.
16. Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011: 317-322.
17. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999; 17: 3736-3744.
18. Vecchi V, Pileri S, Burnelli R, et al. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer 1993; 72: 2049-2057.
19. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 2003; 21: 2026-2033.
20. Guiter C, Dusanter-Fourt I, Copie-Bergman C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004; 104: 543-549.
21. Deepak P, Kumar S Jr, Kishore D, Acharya A. IL-13 from Th2-type cells suppresses induction of antigenspecific Th1 immunity in a T-cell lymphoma. Int Immunol 2010; 22: 53-63.
22. Gunven P, Klein G, Henle G, Henle W, Clifford P. Epstein-Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma. Antibodies to EBV associated membrane and viral capsid antigens in Burkitt lymphoma patients. Nature 1970: 228: 1053- 1056.
23. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol 2006; 34: 399-406.
24. Weiss LM, Chen YY, Liu XF, Shibata D. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 1991; 139: 1259-1265.
25. Tsai SC, Lin SJ, Chen PW, et al. EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood 2009; 114: 109-118.
26. Çavdar AO, Pamir A, Gözdaşoglu S, et al. Hodgkin's disease in children: clinicoepidemiological and viral (Epstein-Barr Virus) analyses. Med Pediatr Oncol 1999; 32: 18-24.
27. Cavdar AO, Yavuz G, Babacan E, et al. Burkitt's Lymphoma in Turkish children: Clinical, Viral [EBV] and Molecular Studies. Leuk Lymphoma 1994; 14: 323-330.